FIND Collaborates with SpeeDx and QuantuMDx
SpeeDx Pty. Ltd. and QuantuMDx Group Ltd. today announced a collaboration with the Foundation for Innovative New Diagnostics (FIND). The global non-profit organization drives development and delivery of diagnostics to combat major diseases affecting the world’s poorest populations. The collaborative project will assess the feasibility of developing low-cost point of care (POC) tests for common sexually transmitted infections (STIs). SpeeDx will use their proprietary Plex PCR® technology to develop multiplex tests for common STIs, including gonorrhoea and Mycoplasma genitalium (Mgen), to be run on the QuantuMDx Q-POCTM POC device.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191107005350/en/
SpeeDx and QuantuMDx collaborate to assess the feasibility of developing low-cost point of care (POC) tests for common sexually transmitted infections (STIs). (Photo: Business Wire)
“We are excited by this collaboration with QuantuMDx and the potential to expand access to high quality testing options to the areas of the world that really need it,” said Dr. Elisa Mokany, SpeeDx Founder and Chief Technology Officer. “Patients around the globe are already benefiting from the clinically relevant information provided by SpeeDx tests, but we are cognisant that the current platforms and processes in use to run these tests do not readily translate to all regions of the world.”
The QuantuMDx Q-POCTM is a battery-operated, microfluidics based, sample-to-answer system for low-cost molecular testing using rapid PCR followed by microarray detection.
“QuantuMDx is always looking to expand the portfolio of diagnostic tests available on the Q-POCTM platform, and this collaboration with SpeeDx is an obvious choice given the proven compatibility of their robust chemistry across a range of platform technologies” said Jonathan O’Halloran, Chief Scientific Officer at QuantuMDx Group. “We have a common goal to enhance the standard of healthcare around the globe, this partnership will accelerate our efforts and combine our lab-standard point of care device with SpeeDx world-class test technology.”
SpeeDx has commercialised a range of tests, principally for sexually transmitted infections, that are in use across Europe, Australia and New Zealand. The flagship Resistance Plus® tests for Mgen and gonorrhoea that include markers for antibiotic resistance/susceptibility have shaped patient management guidelines around the world, providing Resistance Guided Therapy options to clinicians and enabling improved care for patients while fostering antimicrobial stewardship. Resistance Plus® GC recently received FDA Breakthrough designation to accelerate the process towards clearance for use in the U.S., and clinical trials for Resistance Plus® MG are nearing completion with expected U.S. launch early 2020.
SpeeDx has developed a molecular diagnostics test portfolio, principally for infectious diseases, that provides both identification as well as therapeutic guidance capabilities. The company is based in Australia with offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information about SpeeDx please see: https://plexpcr.com
About QuantuMDx Group
QuantuMDx Group is a multinational company with a global vision of empowering the world to control and eradicate disease by making transformative, quality point-of-care diagnostic technologies universally accessible. The company’s flagship device, Q-POC™, is a next generation DNA analyser which delivers the full power of a molecular diagnostics lab in an affordable, simple-to-use, portable, desktop system. Q-POC™ offers true sample collection-to-answer analysis in minutes, in decentralized settings. Headquartered in the UK, QuantuMDx has operations and strategic partnerships in the United States, Asia, Europe and Africa – keeping it at the forefront of molecular diagnostics. For more information go to: www.quantumdx.com: https://quantumdx.com/
Europe, Australia, New Zealand
+61 2 9209 4170
+1 415 202 4445
+ 44 870 803 1234
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ZMC Partners With CommentSold11.11.2019 17:00:00 CET | Press release
CommentSold, Inc. (“CommentSold” or the “Company”) today announced that affiliates of private equity firm ZMC have invested in the Company. Terms of the transaction were not disclosed. Founded in 2017 by CEO Brandon Kruse, CommentSold is a leading provider of multi-channel social commerce technology and managed services to boutique online retailers. The Company provides a variety of commerce enablement services including order intake, payment, fulfillment, live selling tools and analytics which are delivered through a proprietary SaaS platform, allowing customers to sell on social platforms and mobile apps. Mr. Kruse will continue as Chief Executive Officer of the Company. “ZMC’s investment will enable CommentSold to continue to offer best in class services, support, and technology for its growing community of retailers,” said Mr. Kruse. “CommentSold will benefit from ZMC’s active involvement and leadership as we continue to grow our customer base, enhance our technology and expand our
GA-ASI to Conduct Series of Capability Demonstrations in Europe11.11.2019 17:00:00 CET | Press release
General Atomics Aeronautical Systems, Inc. (GA-ASI), a global leader in Remotely Piloted Aircraft (RPA), announced today that they are working with the Hellenic Air Force (HAF) in Greece to conduct a series of demonstration flights for European countries in December. Flights will base out of the HAF’s site in Larissa and use a GA-ASI MQ-9 Guardian RPA to showcase maritime surveillance capabilities, as well as a GA-ASI-developed Detect and Avoid (DAA) system that enables RPA to fly safely in civil airspace alongside manned aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191111005503/en/ “We appreciate the Hellenic Air Force’s support in helping showcase the maritime surveillance and civil airspace integration capabilities of our unmanned aircraft in Europe.” - Linden Blue, CEO, GA-ASI. (Photo: Business Wire) “We appreciate the HAF’s support in helping showcase the maritime surveillance and civil airspace integration
Novarica Market Navigator Report Validates FINEOS is the Market Leader in Life, Accident and Health Claims Systems in North America By Client Base11.11.2019 14:20:00 CET | Press release
FINEOS Corporation (ASX: FCL), the leading core insurance platform vendor for life, accident and health (LA&H), was profiled in the recent Novarica Market Navigator Life/Health Claims Systems (September 2019). The report shows FINEOS has the largest client base for LA&H Claims in North America covering both individual and group markets. The Novarica Market Navigator report provides an overview of available stand-alone claims systems for Life, Accident & Health insurers. FINEOS was profiled across a wide range of criteria including functionality, technology, differentiators and implementation capabilities as shown in this report excerpt. The report found that claims gained ground as one of the most critical capabilities an insurer needs to meet heightened customer expectations to match service levels provided across all types of business including retailers and financial services. Additional findings reveal that advanced claims processing capabilities like triage-based STP, skill-based
The New 2020 Report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Gives Highest Evidence Rating to Endobronchial Valves, including the Zephyr Valve, for Treatment of Emphysema / COPD11.11.2019 13:30:00 CET | Press release
Pulmonx Corporation, a leader in therapeutic pulmonary device technologies, announced today that the 2020 update from the Global Initiative for Chronic Obstructive Disease (GOLD) has upgraded the evidence level rating for bronchoscopic lung volume reduction (BLVR) with endobronchial valves, including the Zephyr Valve, for the treatment of emphysema / chronic obstructive pulmonary disease (COPD). In the newly released report, GOLD upgraded the evidence rating to “A”, the highest evidence rating, for BLVR with endobronchial valves.1 This evidence rating is based on results from well-designed randomized clinical trials with data from more than two clinical trials involving a substantial number of patients, including those treated with the Zephyr Valve. The Zephyr Valve is a minimally-invasive treatment option that has been shown to improve quality of life of emphysema patients by allowing them to experience less shortness of breath and be more active.2 This press release features multimed
TREMFYA®▼ (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic Arthritis Studies11.11.2019 13:26:00 CET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced 24-week Phase 3 data showing a significantly greater proportion of patients with active psoriatic arthritis (PsA) treated with TREMFYA® ▼ (guselkumab) achieved at least a 20 percent improvement in disease signs and symptoms (American College of Rheumatology ACR20 response) compared to placebo.1,2 These findings represent the primary endpoints of the DISCOVER-1 and DISCOVER-2 Phase 3 studies, which were designed to evaluate the efficacy and safety of investigational use of guselkumab for the treatment of adult patients with active PsA.1,2 These results were presented as part of an oral plenary session (abstract 0807) and a late-breaking poster session (abstract L13), respectively, at the American College of Rheumatology and Association of Rheumatology Professionals (ACR/ARP) 2019 Annual Meeting taking place 8-13 November in Atlanta.1,2 Janssen presented a total of 30 abstracts at the meeting. “People living with p
Wipro Implements SAP S/4HANA® for Sydney Water11.11.2019 12:55:00 CET | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced the successful implementation of SAP S/4HANA® software for Sydney Water, a statutory state-owned corporation wholly owned by the New South Wales Government. Wipro has also integrated modules of Industry-Specific Solution for the Utilities Industry (IS-U), Customer Relationship Management (CRM) and Flexible Real Estate Management (RE-FX) globally for the customer. Leveraging SAP S/4HANA, Sydney Water will be able to deploy state-of-the-art features in its billing and customer services, enabling simplified billing processes and next-generation transformation of customer self-service. Built with additional capabilities such as holistic view of customer data and intelligent mobile-based interaction, this solution will provide end users with an interactive interface. It will enable a 360-degree view of the customer, resulting in incre